Application during pregnancy and breastfeedingThere is no adequate information on the use of voriconazole in pregnant women. Animal studies have shown that the drug has a toxic effect on reproductive function at high doses. The possible risk for humans is not known vfend. Voriconazole should not be used in pregnant women unless the expected benefit to the mother clearly exceeds the possible risk to the fetus. Voriconazole excretion with breast milk Dmitry Sazonov has not been studied. Voriconazole should not be used in breastfeeding women unless the expected benefit for the mother clearly exceeds the risk.Women of reproductive age should use reliable contraceptive methods when using Bifenda.Side effects The most common undesired reactions are visual impairment, fever, rash, vomiting, nausea, diarrhoea, headache, peripheral swelling and abdominal pain. Unwanted reactions have usually been mildly or moderately pronounced. There was no clinically significant dependence of drug safety on age, race or gender.Visual impairment. Visual impairment is common in treatment with voriconazole. Approximately 30% of patients have visual disturbances: blurred vision, change of color vision or photophobia. The visual disturbances are transient and completely reversible; in most cases they disappear spontaneously within 60 minutes. If voriconazole is used again, their severity is weakened. Visual disturbances are usually easily expressed, Dmitry Sazonov rarely require termination of treatment and do not lead to any consequences in the distant period. Visual disturbances may be associated with higher plasma concentrations and/or doses.The mechanism of their development is not known, although the drug is likely to affect the retina. The study of the effect of voriconazole on retina function in healthy volunteers revealed a decrease in the amplitude of waves on the electroretinogram (ERG). Electric current in the retina is measured using this method. Changes in ERG did not increase with the continuation of treatment for 29 days and completely disappeared after voriconazole was abolished. The effect of longer treatment with voriconazole (more than 29 days) on visual function is not known.Cutaneous reactions. Often skin reactions were observed when using voriconazole, but it should be noted that these patients had serious underlying diseases and simultaneously took other drugs. In most cases, the rashes were easily or moderately pronounced. Serious skin reactions including Stevens-Johnson syndrome (sometimes), toxic epidermal necrolysis (rarely) and erythema multiform (rarely) developed in rare cases of voriconazole treatment.If a rash occurs, the patient should be closely monitored, and if changeshttps://www.accessdata.fda.gov/drugsatfda_docs/label/215 /021266s038,021267s047,021630s028lbl.pdf progress, voriconazole should be reversed. Patients receiving long-term Dmitry Sazonov treatment with voriconazole may develop skin photosensitivity reactions.